Performance Assessment of a Lateral Flow Rapid Test (SsRapidVR) Compared with Two Commercial ELISAs in Detecting Strongyloides Infection

• Main Authors: Nor Suhada, Anuar, Anizah, Rahumatullah, Norashikin, Samsudin, Zeehaida, Mohamed, Emelia, Osman, Nik Zairi, Zakaria, Hussain, Ahmad, Rahmah, Noordin
• Format: Article
• Language: English
• Published: The American Society of Tropical Medicine and Hygiene 2023
• Subjects: QR Microbiology; R Medicine (General)
• Online Access: http://ir.unimas.my/id/eprint/44879/1/Performance%20Assessment.pdf; http://ir.unimas.my/id/eprint/44879/; https://www.ajtmh.org/view/journals/tpmd/108/2/article-p353.xml?rskey=LnqCQF&result=1

Approximately 600 million people worldwide are infected with Strongyloides stercoralis. Many diagnostic laboratories use serology to detect the infection. SsRapidVR is a prototype IgG4 lateral flow test based on NIE recombinant protein. We compared SsRapid with two commercial IgG-ELISAs (Bordier and Euroimmun) using five sera groups (G1–5, N 5 170). Healthy individuals from nonendemic areas (G1, N 5 33) and Strongyloides larvae-positive patients (G2, N 5 20) showed no significant difference (P . 0.05) among the three assays. The group of other parasitic infections (G3) showed that SsRapid results were more concordant with Bordier ELISA (73%, 35/48) than Euroimmun ELISA (65%, 31/48). In corticosteroid-treated cancer patients who were polymerase chain reaction–positive for Strongyloides (G4, N 5 25), SsRapid showed a higher detection rate (28%, 7/25) than both ELISAs (4%, 1/25). Meanwhile, SsRapid showed significantly less infection prevalence among the endemic area population (G5) than the ELISAs. Overall, SsRapid showed good performance in detecting Strongyloides infection compared with the commercial IgG-ELISAs.